2. Search Result
Search Result
Results for "

TBARS

" in MedChemExpress (MCE) Product Catalog:

17

Inhibitors & Agonists

1

Biochemical Assay Reagents

6

Natural
Products

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-D1005A
    Poloxamer 188

    PEG-PPG-PEG, 8800 (Average Mn)

    		 Environmental Pollutants Biochemical Assay Reagents Inflammation/Immunology
    Poloxamer 188 is a nonionic linear copolymer with surfactant properties. Poloxamer 188 exhibits anti-thrombotic, anti-inflammatory, and cytoprotective activities in various tissue injury models. Poloxamer 188 can be used for drug delivery .
    Poloxamer 188
  • HY-B1330
    Proglumide
    1 Publications Verification

    		 Cholecystokinin Receptor Neurological Disease Endocrinology Cancer
    Proglumide is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide selective blocks CCK’s effects in the central nervous system (CNS). Proglumide has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide also has antiepileptic and antioxidant activities .
    Proglumide
  • HY-103354
    Proglumide sodium
    1 Publications Verification

    		 Cholecystokinin Receptor Neurological Disease Endocrinology Cancer
    Proglumide sodium is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide sodium selective blocks CCK’s effects in the central nervous system (CNS). Proglumide sodium has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide sodium also has antiepileptic and antioxidant activities .
    Proglumide sodium
  • HY-121271
    Kadsurin

    		Others Inflammation/Immunology
    Kadsurin, a natural compound from the stems of Kadsura heteroclita (Schizandraceae), results in significant decreases of CCL4- induced lipid-peroxidation products, such as thiobarbituric acid reactive substances (TBA-RS), conjugated dienes and fluorescent products in the liver of mice .
    Kadsurin
  • HY-W587784
    Norbixin

    		PPAR Metabolic Disease
    Norbixin is a carotenoid that has been found in B. orellana.It binds to PPARγ in a cell-free assay (Ki = 1.15 μM) . Norbixin attenuates hyperglycemia, hyperinsulinemia, and insulin resistance, as well as decreases serum lipid levels and cardiac levels of thiobarbituric acid reactive substances (TBARS) and glutathione (GSH) in a rat model of cardio-metabolic syndrome .
    Norbixin
  • HY-174419
    TFSeB

    		Monoamine Oxidase Reactive Oxygen Species (ROS) NF-κB Bcl-2 Family Cholinesterase (ChE) Neurological Disease Inflammation/Immunology
    TFSeB is an orally active neuroprotective agent. TFSeB can reduce Streptozotocin (STZ) (HY-13753) induced MAO-B and AChE activity. TFSeB exerts neuroprotective effects by increasing the expression of BCL-2, BDNF, NRF2, and decreasing the expression of BAX. TFSeB can reduce lipid peroxidation (TBARS) and reactive oxygen species (ROS) levels. TFSeB can reduce neuroinflammation. TFSeB can be used for research on Alzheimer’s disease .
    TFSeB
  • HY-N4280
    7,8-Dimethoxycoumarin
    1 Publications Verification

    		 Na+/K+ ATPase Glutathione Peroxidase NF-κB p38 MAPK Interleukin Related Neurological Disease Metabolic Disease Inflammation/Immunology
    7,8-Dimethoxycoumarin is a coumarin compound derived from Artemisia caruifolia with oral activity. 7,8-Dimethoxycoumarin inhibits mitochondrial permeability transition pore and H +/K +-ATPase, and exhibits antioxidant, anti-inflammatory, renoprotective, neuroprotective and gastroprotective effects. 7,8-Dimethoxycoumarin reduces lipid peroxidation (TBARS), increases GSH levels, inhibits myeloperoxidase (MPO) activity, and regulates the expression of inflammatory factors by inhibiting the NF‑κB and MAPK pathways. 7,8-Dimethoxycoumarin ameliorates gastric mucosal injury, alleviates renal tissue lesions and relieves neuropathic pain. 7,8-Dimethoxycoumarin can be used in studies related to acute renal failure, trigeminal neuralgia and gastritis .
    7,8-Dimethoxycoumarin
  • HY-N16527
    7-O-Galloyl-D-sedoheptulose

    		TNF Receptor Interleukin Related NADPH Oxidase Reactive Oxygen Species (ROS) NF-κB COX NO Synthase JNK AP-1 TGF-β Receptor Metabolic Disease
    7-O-Galloyl-D-sedoheptulose is an orally effective polyphenolic compound. 7-O-Galloyl-D-sedoheptulose lowers the serum levels of glucose, leptin, insulin, C-peptide, resistin, TNF-α, IL-6, and increases the serum level of adiponectin. 7-O-Galloyl-D-sedoheptulose significantly reduces the levels of ROS and lipid peroxidation products (TBARS) by down-regulating the protein expression of NADPH oxidase subunit Nox-4 and p22phox. 7-O-Galloyl-D-sedoheptulose down-regulates NF-κB and related pro-inflammatory factors (COX-2, iNOS), inhibits the phosphorylation of JNK and the activity of its downstream AP-1. 7-O-Galloyl-D-sedoheptulose reduces the expression of TGF-β1 and fibronectin, indicating its potential in anti-tissue fibrosis. 7-O-Galloyl-D-sedoheptulose can be used for the study of type 2 diabetes and its hepatic and pancreatic complications .
    7-O-Galloyl-D-sedoheptulose
  • HY-W402074
    5-Acetamide-Butenolide

    Butenolide

    		 Mitochondrial Metabolism Reactive Oxygen Species (ROS) Metabolic Disease
    5-Acetamide-Butenolide (Butenolide) is a mycotoxin with pro-oxidant activity, which is found in Fusarium. 5-Acetamide-Butenolide disrupts the mitochondrial membrane potential in primary neonatal rat cardiomyocytes. 5-Acetamide-Butenolide also induces the production of thiobarbituric acid reactive substances (TBARS) in isolated rat myocardial mitochondria. 5-Acetamide-Butenolide increases the production of reactive oxygen species (ROS), decreases the levels of GSH and reduces the viability of HepG2 cells .
    5-Acetamide-Butenolide
  • HY-103354A
    Proglumide hemicalcium

    		Cholecystokinin Receptor Neurological Disease Endocrinology Cancer
    Proglumide hemicalcium is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide hemicalcium selective blocks CCK’s effects in the central nervous system (CNS). Proglumide hemicalcium has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide hemicalcium also has antiepileptic and antioxidant activities .
    Proglumide hemicalcium
  • HY-103354R
    Proglumide sodium (Standard)

    		Reference Standards Cholecystokinin Receptor Neurological Disease Endocrinology Cancer
    Proglumide (sodium) (Standard) is the analytical standard of Proglumide (sodium). This product is intended for research and analytical applications. Proglumide sodium is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide sodium selective blocks CCK’s effects in the central nervous system (CNS). Proglumide sodium has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide sodium also has antiepileptic and antioxidant activities .
    Proglumide sodium (Standard)
  • HY-B1330R
    Proglumide (Standard)

    		Cholecystokinin Receptor Reference Standards Neurological Disease Endocrinology Cancer
    Proglumide (Standard) is the analytical standard of Proglumide. This product is intended for research and analytical applications. Proglumide is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide selective blocks CCK’s effects in the central nervous system (CNS). Proglumide has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide also has antiepileptic and antioxidant activities .
    Proglumide (Standard)
  • HY-103388
    NCX 466

    		COX TGF-β Receptor Glutathione Peroxidase Inflammation/Immunology
    NCX 466 is an orally active COX-1 and COX-2 inhibitor that exhibits anti-inflammatory and analgesic effects. Additionally, NCX 466 acts as a NO donor, exerting anti-inflammatory and antioxidant effects by improving microcirculation. NCX 466 significantly reduces the levels of transforming growth factor-β (TGF-β) and oxidative stress markers (such as thiobarbituric acid reactive substances (TBARS) and 8-hydroxy-2'-deoxyguanosine (8-OHdG)), and it decreases leukocyte recruitment during inflammation by reducing myeloperoxidase (MPO) activity, thereby preventing bleomycin (HY-108345)-induced pulmonary fibrosis in mice .
    NCX 466
  • HY-130743
    Dieugenol

    Bis-eugenol; Dehydrodieugenol

    		 Parasite Infection
    Dieugenol is a neolignan that has been found in N. leucantha and has antioxidative and antiprotozoal activities. It inhibits the formation of thiobarbituric acid reactive substances (TBARS) and scavenges superoxide anions, but not hydroxyl radicals, in cell-free assays. It has anti-trypanosomal activity against T. cruzi amastigotes and trypomastigotes (IC50s=15.1 and 11.5 μM, respectively) but is cytotoxic to NCTC L-929 fibroblasts with a 50% cytotoxic concentration (CC50) value of 58.2 μM.2 Dieugenol (15 μM) disrupts the integrity of the T. cruzi trypomastigote plasma membrane but does not induce the production of reactive oxygen species (ROS) in trypomastigotes or LPS-stimulated and unstimulated isolated mouse peritoneal macrophages.
    Dieugenol
  • HY-177995
    MiADMSA

    Monoisoamyl meso-2,3-dimercaptosuccinic acid

    		 Reactive Oxygen Species (ROS) SOD Neurological Disease Cancer
    MiADMSA (Monoisoamyl meso-2,3-dimercaptosuccinic acid) is an orally active thiol chelator that can effectively remove heavy metals such as arsenic and lead from the body of animals. Arsenic binds with two vicinal sulfhydryl groups available in MiADMSA leading to marked reduction in body arsenic burden and also marked reduction in various oxidative stress parameters and antioxidant enzymes like-ROS, nitrite, TBARS, GSH, SOD and catalase. MiADMSA attenuates urinary bladder carcinogenesis, protects against oxidative stress, ameliorates copper-induced histopathology, reverses neurotoxicity, and is safe in animals. MiADMSA can be used in studies of bladder cancer, arsenic, and lead-induced developmental neurotoxicity .
    MiADMSA
  • HY-W747910A
    S584 dihydrochloride

    		Drug Metabolite Inflammation/Immunology
    S584 dihydrochloride is a catechol metabolite of the oral-effective Piribedil (HY-12707), with anti-lipid peroxidation activity. S584 dihydrochloride significantly inhibits lipid peroxidation in rat synaptosomes under basal conditions and Fe³⁺ stimulation. S584 dihydrochloride significantly antagonizes the increase in thiobarbituric acid reactive substances (TBARS) in the brains of mice exposed to high oxygen and under normal air conditions .
    S584 dihydrochloride
  • HY-N13285
    (-)-Epigallocatechin-4'-O-methylether

    (-)-EGC-4'-O-ME

    		 Drug Derivative Metabolic Disease Inflammation/Immunology
    (-)-Epigallocatechin-4'-O-methylether ((-)-EGC-4'-O-ME) is an orally active natural phenolic catechin with antioxidant, free radical-scavenging and hepatoprotective activities. (-)-Epigallocatechin-4'-O-methylether interferes with radiation-induced free radical formation, scavenges DPPH free radicals, inhibits carbon tetrachloride-induced increases in serum GOT and GPT, suppresses carbon tetrachloride-induced TBA-RS formation, and counteracts carbon tetrachloride-induced hepatocyte toxicity. (-)-Epigallocatechin-4'-O-methylether binds specifically to human serum albumin. (-)-Epigallocatechin-4'-O-methylether can be used in studies related to liver injury .
    (-)-Epigallocatechin-4'-O-methylether

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: